Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

The presence of barriers, such as the blood–brain barrier (BBB) and brain–tumor barrier
(BTB), limits the penetration of antineoplastic drugs into the brain, resulting in poor response …

Lung cancer (LC) continues to pose a significant global medical burden, necessitating a
comprehensive understanding of its molecular foundations to establish effective treatment …

Small cell lung cancer (SCLC) is a type of neuroendocrine tumor with high malignancy and
poor prognosis. Besides the de novo SCLC, there is transformed SCLC, which has similar …

Cancer is the second leading cause of death worldwide. Majority of recent research efforts in
the field aim to address why cancer resistance to therapy develops and how to overcome or …

Vascular epidermal growth factor receptor-2 (VEGFR-2), as an important tyrosine
transmembrane protein, plays an important role in regulating endothelial cell proliferation …

Introduction Approximately 10% of EGFR mutations (EGFRmuts) are uncommon
(ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with …

Background Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer
(NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth …

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have
demonstrated efficacy in patients with EGFR-mutant non-small-cell lung cancer; however …